Evidence map›Paper›PMID 24494689›Full record

ReviewThe European journal of neuroscience2014

The neurobiology of skeletal pain.

Patrick W Mantyh

Abstract readReview
In one paragraph

Review in The European journal of neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Patrick W MantyhDepartment of Pharmacology and Arizona Cancer Center, University of Arizona, Tucson, AZ, 85716, USA.
University of Arizona · US

Funding

Peripheral Nociceptors in Persistent PainR01NS023970 · NINDS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MANTYH, PATRICK WILLIAM · 1987 to 2019
$3.7M
PERIPHERAL NOCICEPTORS IN PERSISTENT PAINR37NS023970 · NINDS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MANTYH, PATRICK WILLIAM · 2001 to 2007
$2.9M
Preventive Analgesia for Bone Cancer PainR01CA154550 · NCI · UNIVERSITY OF ARIZONA · PI MANTYH, PATRICK WILLIAM · 2011 to 2015
$1.6M
METASTATIC PROSTATE CANCER-INDUCED BONE PAINR01CA157449 · NCI · UNIVERSITY OF ARIZONA · PI MANTYH, PATRICK WILLIAM · 2011 to 2015
$1.5M
NCI NIH HHS CA154550NCI NIH HHS CA157449NCI NIH HHS R01 CA154550NCI NIH HHS R01 CA157449NINDS NIH HHS NS023970NINDS NIH HHS R01 NS023970NINDS NIH HHS R37 NS023970
6 · The paper itself

Abstract

Disorders of the skeleton are one of the most common causes of chronic pain and long-term physical disability in the world. Chronic skeletal pain is caused by a remarkably diverse group of conditions including trauma-induced fracture, osteoarthritis, osteoporosis, low back pain, orthopedic procedures, celiac disease, sickle cell disease and bone cancer. While these disorders are diverse, what they share in common is that when chronic skeletal pain occurs in these disorders, there are currently few therapies that can fully control the pain without significant unwanted side effects. In this review we focus on recent advances in our knowledge concerning the unique population of primary afferent sensory nerve fibers that innervate the skeleton, the nociceptive and neuropathic mechanisms that are involved in driving skeletal pain, and the neurochemical and structural changes that can occur in sensory and sympathetic nerve fibers and the CNS in chronic skeletal pain. We also discuss therapies targeting nerve growth factor or sclerostin for treating skeletal pain. These therapies have provided unique insight into the factors that drive skeletal pain and the structural decline that occurs in the aging skeleton. We conclude by discussing how these advances have changed our understanding and potentially the therapeutic options for treating and/or preventing chronic pain in the injured, diseased and aged skeleton.

Indexed as

Anabolic AgentsAnalgesicsAnimalsBone and BonesHumansMusculoskeletal PainNeuralgiaNociceptive PainAnabolic AgentsAnalgesicsagebonecartilageCRPSmarrownociceptor

Identifiers

PMID24494689
PMCPMC4453827
OpenAlexW2118132716

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.